20140163.TNBC
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- G2M_CHECKPOINT+0.400
- MITOTIC_SPINDLE+0.380
- E2F_TARGETS+0.370
- TNFA_SIGNALING_VIA_NFKB+0.310
- PROTEIN_SECRETION+0.290
- CHOLESTEROL_HOMEOSTASIS+0.230
- UV_RESPONSE_DN+0.230
- ANDROGEN_RESPONSE+0.220
- ALLOGRAFT_REJECTION+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.240
- ADIPOGENESIS-0.230
- ESTROGEN_RESPONSE_EARLY-0.220
- BILE_ACID_METABOLISM-0.180
- MYC_TARGETS_V2-0.140
- DNA_REPAIR-0.130
- FATTY_ACID_METABOLISM-0.130
- PEROXISOME-0.130
- XENOBIOTIC_METABOLISM-0.130
- ESTROGEN_RESPONSE_LATE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0AV-01A-31R-A115-07 | — | E | 0.852 |
| 2 | TCGA-85-8353-01A-21R-2296-07 | — | cohortSQ1 | 0.817 |
| 3 | TCGA-CU-A0YN-01A-21R-A10U-07 | — | — | 0.816 |
| 4 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.790 |
| 5 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.789 |
| 6 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.785 |
| 7 | TCGA-CV-6959-01A-11R-1915-07 | — | — | 0.776 |
| 8 | DRR168559 | — | — | 0.773 |
| 9 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.770 |
| 10 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |